Homologous recombination status drives disease-free survival in patients with advanced ovarian cancer undergoing hyperthermic intraperitoneal chemotherapy at the time of interval debulking surgery.

Khrystyna Levytska, SeungYong Han, Allison E Axtell, Malaika W Amneus, Brandon Ing, Scott E Lentz

Abstract read

In one paragraph

Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Considering homologous recombination deficiency status in HIPEC: could molecular testing someday drive "targeted" surgery?Gynecologic oncology reports · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Khrystyna LevytskaDivision of Gynecologic Oncology, Kaiser Permanente-Los Angeles Medical Center, Los Angeles, CA, USA.

SeungYong HanDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.

Allison E AxtellDivision of Gynecologic Oncology, Kaiser Permanente-Los Angeles Medical Center, Los Angeles, CA, USA.

Malaika W AmneusDivision of Gynecologic Oncology, Kaiser Permanente-Panorama City Medical Center, Los Angeles, CA, USA.

Brandon IngDepartment of Obstetrics and Gynecology, Kaiser Permanente Hawaii, Honolulu, HI, USA.

Scott E LentzDivision of Gynecologic Oncology, Kaiser Permanente-Los Angeles Medical Center, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Describe surgical outcomes of patients undergoing HIPEC with cisplatin (C) alone or cisplatin/paclitaxel (CP), compared to interval debulking surgery (IDS) without HIPEC, and stratify disease-free survival (DFS) by treatment and homologous recombination (HR) status. Methods: Retrospective chart review of patients with advanced ovarian cancer undergoing IDS with and without HIPEC between 2018-2024. DFS was compared using a log rank test. Cox proportional hazards model was used to test association between treatment group and recurrence. Results: 74 patients were included: 20 in no HIPEC, 28 in HIPEC-C, and 26 in HIPEC-CP groups. Duration of surgery was shortest in no HIPEC group (159 ± 64 min Conclusions: Addition of paclitaxel to cisplatin at the time of IDS with HIPEC had no effect on

Indexed as

HIPECHomologous recombination statusIntervaldebulking surgeryOvarian cancer

Identifiers

PMID41293570

DOI10.1016/j.gore.2025.101981

PMCPMC12641191

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.